Learn More >

Ministry Status: Routine Monitoring and Engagement

Ontario Public Drug Programs

EO Decisions and CED Recommendations

The information below is intended only to provide the recommendations and rationale from the Committee to Evaluate Drugs (CED) and the Executive Officer decisions regarding the listing of products on the Formulary, funding of cancer drugs through the New Drug Funding Program, funding through the Exceptional Access Program, or funding through the Special Drugs Program.

For further details on what types of information is provided, please refer to the Transparency of the Drug Review Process.

Do not rely upon any of the information provided on this site for medical diagnosis or treatment. Please consult your primary health care provider about any personal health concerns. This website does not provide any medical diagnosis, symptom assessment, health counseling or medical opinion for individual users. The information contained on this site is intended for information purposes only and does not constitute medical advice for patients. For more detailed information on prescription drugs, please consult a qualified healthcare professional.

 

Brand Name Generic Name
January 2016
Adcetris for systemic anaplastic large cell lymphoma brentuximab
Afinitor for renal angiomyolipoma associated with tuberous sclerosis complex everolimus
Alimta for maintenance treatment of non-small cell lung cancer pemetrexed
Actemra for juvenile arthritis tocilizumab
Bystolic nebivolol
Cubicin daptomycin
Edarbi azilsartan medoxomil
Edarbyclor azilsartan medoxomil / chlorthalidone
Erivedge vismodegib
Giotrif afatinib
Inspra for heart failure eplerenone
Jetrea ocriplasmin
Kadcycla trastuzumab emtansine
Latuda for schizophrenia lurasidone hydrochloride
Stivarga for gastrointestinal stromal tumours regorafenib
Stivarga for metastatic colorectal cancer regorafenib
Tafinlar dabrafenib
TOBI Podhaler tobramycin inhalation powder
Tudorza Genuair aclidinium
Xarelto for pulmonary embolism rivaroxaban
May 2015
Adcetris - Hodgkin lymphoma brentuximab
Androderm 24.3 mg transdermal patch testosterone
Caripul epoprostenol
Clindoxyl ADV Gel clindamycin 1%/ benzoyl peroxide 3%
Dovobet gel calcipotriol / betamethasone
Epuris isotretinoin
Esbriet pirfenidone
Fycompa perampanel
Genotropin somatropin
Jentadueto linagliptin / metformin
Mekinist trametinib
Nutropin AQ® NuSpin® 5 and 20 somatropin
Pentasa 1 gram extended-release tablet 5-aminosalicylic acid
Perjeta pertuzumab / trastuzumab
Picato ingenol mebutate topical gel
Revlimid lenalidomide
Samsca tolvaptan
Sublinox zolpidem
Tecfidera dimethyl fumarate
Trisenox arsenic trioxide
Votrient pazopanib
Zytiga abiraterone
January 2014
Avastin – GBM re-evaluation bevacizumab
November 2012
Champix varenicline
March 2012
Januvia sitagliptin
October 2011
Avastin – GBM bevacizumab
Fludara – CLL fludarabine tablet
Metvix methyl aminolevulinate
Rituxan – CLL rituximab
May 2011
Adcirca tadalafil
Afinitor everolimus
Orencia abatacept
Torisel temsirolimus
Vidaza azacitidine
April 2011
Erbitux – head & neck cancer cetuximab
Erbitux – metastatic colorectal cancer cetuximab
Prolastin alpha1-proteinase inhibitor
Simponi – ankylosing spondylitis golimumab
Simponi – psoriatic arthritis golimumab
Simponi – rheumatoid arthritis golimumab
February 2011
Tysabri natalizumab
January 2011
Gleevec – ALL imatinib
Long-Acting medications for Attention Deficit Hyperactivity Disorder (ADHD) long-acting medications for attention deficit hyperactivity disorder (ADHD)
Sprycel – ALL dasatinib
Thelin sitaxsentan
November 2010
Leukotriene Receptor Antagonists
(Singulair, Accolate)
leukotriene receptor antagonists
(montelukast, zafirlukast)
August 2010
Levemir Penfill insulin detemir
Lantus SoloStar insulin glargine
Humalog Mix50 insulin lispro/insulin lispro protamine
Cymbalta for DPN duloxetine for DPN
Azilect rasagiline
July 2010
Actonel 75mg and 150mg risedronate sodium
Combination treatment for Pulmonary Arterial Hypertension (PAH)
Fosavance 70/140 alendronate-cholecalciferol
Revatio sildenafil
Volibris ambrisentan
June 2010
Seroquel XR quetiapine fumarate
Mezavant mesalamine (5-ASA)
Ralivia tramadol hydrochloride ER
Tridural tramadol hydrochloride ER
Zytram XL tramadol hydrochloride XL
Xarelto rivaroxaban
April 2010
Advagraf tacrolimus (extended-release)
Abraxane nab-paclitaxel
Resultz isopropyl myristate
Faslodex fulvestrant
March 2010
Exjade deferasirox
Kaletra pediatric tablet lopinavir / ritonavir
February 2010
Aldara imiquimod
Atacand candesarten cilexetil
Biphentin methylphenidate extended release
Fluanxol Depot flupenthixol decanoate
Nuvaring etonogestrel / ethinyl estradiol
Rebif initiation package interferon beta1a
Vantas histrelin acetate
December 2009
Myozyme alglucosidase alfa
November 2009
Cubicin daptomycin
Eprex - additional dosage forms epoetin alfa - additional dosage forms
Invega paliperidone
Omnaris ciclesonide
One-Alpha alfacalcidol
October 2009
Adderall XR mixed amphetamine salts
Celsentri maraviroc
Cosopt Preservative Free dorzolamide/timolol
Diovan-HCT valsartan/ hydrochlorothiazide
Exelon Patch rivastigmine patch
Rasilez aliskiren
Stalevo levodopa/ carbidopa/ entacapone
Xeloda capecitabine (as component of CAPOX regimen)
September 2009
Avastin - for metastatic colorectal cancer bevacizumab
Elaprase idursulfase
April 2009
Posanol posaconazole
Revlimid – myelodysplastic syndrome lenalidomide
Seasonale levonorgestrel / ethinyl estradiol
March 2009
Intelence etravirine
Lantus insulin glargine
February 2009
Hyzaar losartan/hydrochlorothiazide
Vectibix panitumumab
January 2008
Aclasta – osteoporosis zoledronic acid
Nexavar – hepatocellular carcinoma sorafenib
Rituxan – rheumatoid arthritis rituximab
December 2008
Levaquin 750mg levofloxacin
Sensipar cinacalcet
Sprycel – chronic myeloid leukemia dasatinib
November 2008
Cipralex escitalopram
Combigan 10mL – new package size brimonidine/timolol
October 2008
Dovobet calcipotriol/betamethasone
Eloxatin – adjuvant treatment of colorectal cancer oxaliplatin
Eloxatin – metastatic colorectal cancer oxaliplatin
Nexavar – metastatic renal cell carcinoma sorafenib
August 2008
Alimta – non-small cell lung cancer pemetrexed
Aromasin – early breast cancer exemestane
Gemzar – metastatic breast cancer gemcitabine hydrochloride
Hycamtin – small cell lung cancer topotecan
Kaletra lopinavir/ritonavir
MabCampath alemtuzumab
Trosec trospium chloride
Xeloda – gastric cancer capecitabine
June 2008
Altace HCT ramipril/hydrochlorothiazide
Aricept RDT donepezil rapidly dissolving tablet
Denavir penciclovir
Exjade deferasirox
Lucentis ranibizumab
Truvada emtricitabine/tenofovir disoproxil fumarate
May 2008
Alvesco ciclesonide
DDAVP Melt desmopressin
Elaprase idursulfase
Hypurin insulin porcine
Sutent – MRCC sunitinib
January 2008
Prezista darunavir
Linessa desogestrel/ethinyl estradiol
Yasmin drospirenone/ethinyl estradiol
Femara letrozole
Altace 15mg capsule ramipril 15mg capsule
October 2007
Duragesic 12 fentanyl 12.5mcg/hr transdermal patch
Altace Plus Felodipine ramipril/felodipine
Avalide irbesartan/hydrochlorothiazide
Caelyx – recurrent ovarian cancer pegylated liposomal doxorubicin
Humira – psoriatic arthritis adalimumab
Hycamtin – recurrent ovarian cancer topotecan
Sutent – GIST sunitinib
Taxol – recurrent ovarian cancer paclitaxel
Vfend voriconazole
July 2007
Actonel Plus Calcium risedronate sodium/calcium carbonate
Alimta - MPM pemetrexed
Diovan valsartan
Enablex darifenacin
Fosavance alendronate/cholecalciferol
Gleevec - CML imatinib mesylate
Gleevec - GIST imatinib mesylate
OxyContin oxycodone hydrochloride

For More Information

Call ServiceOntario, Infoline at:
1-866-532-3161 (Toll-free)
In Toronto, (416) 314-5518
TTY 1-800-387-5559.
In Toronto, TTY 416-327-4282
Hours of operation : 8:30am - 5:00pm